Price Alert

Puma Biotechnology Inc. (PBYI)

NASDAQ: PBYI · Real-Time Price · USD

5.75

0.43 (8.08%)

At close: Aug 15, 2025, 1:07 PM

8.08% (1D)

Bid	5.7
Market Cap	289.43M
Revenue (ttm)	232.71M
Net Income (ttm)	38.07M
EPS (ttm)	0.99
PE Ratio (ttm)	5.8
Forward PE	15.98
Analyst	Buy

Ask	6.78
Volume	550,997
Avg. Volume (20D)	473,387
Open	5.36
Previous Close	5.32
Day's Range	5.29 - 5.76
52-Week Range	2.23 - 5.76
Beta	1.29

About PBYI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PBYI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PBYI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Puma Biotechnology has released their quartely earnings on Aug 7, 2025:

Revenue of $49.2M misses estimates by $2.07M, with 4.46% YoY growth.

EPS of 0.15 exceeds estimates by 0.08, with 400.00% YoY growth.

Next Earnings Release

Puma Biotechnology Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

+19.73%

Puma Biotechnology shares are trading higher after... Unlock content with Pro Subscription

News

2 days ago · zacks.com

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 days ago · zacks.com

Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?

Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

1 week ago · businesswire.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the issuance of inducement awards to three new hires, as required under Nasdaq Listing Rule 5635(c)(4).

6 days ago · zacks.com

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.

6 days ago · fool.com

Puma (PBYI) Q2 Revenue Rises 11%

1 week ago · seekingalpha.com

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan H. Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber ...

1 week ago · zacks.com

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

Puma Biotech (PBYI) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.05 per share a year ago.

3 weeks ago · businesswire.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

LOS ANGELES--(BUSINESS WIRE)--On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second quarter of 2025.

1 month ago · zacks.com

Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns

INTU, NTGR, PBYI and DASH make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.

1 month ago · zacks.com

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

Load More News